TG Therapeutics, Inc. (TGTX)Healthcare | Biotechnology | Morrisville, United States | NasdaqCM
55.01 USD
-2.11
(-3.694%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 54.51 -0.50 (-0.500%) ⇩ (July 13, 2026, 7:51 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 4:09 a.m. EDT
The immediate outlook is driven by a powerful convergence of clinical catalysts and aggressive speculative positioning. TG Therapeutics is launching Phase 2 trials for Briumvi in schizophrenia, a strategic pivot that expands its addressable market beyond the existing multiple sclerosis indication, while recent financial results have successfully raised revenue guidance. This fundamental inflection point has triggered a 'hot money' response in the options chain, where traders are stacking heavy call exposure at the $60 resistance level, suggesting a high-conviction bet on a breakout from the current consolidation. The stock has already rallied significantly off its lows, yet the momentum remains intact as the market prices in the potential for a blockbuster readout. However, investors must remain cautious of the inherent biotech binary risk; while the current trajectory is strongly upward, the lack of a dividend and the company's reliance on future trial success mean this is a volatile, high-beta play rather than a stable income vehicle. The statistical models offer only a weak lean, which is appropriate given the noise, but the fundamental and sentiment signals align to support a near-term bullish thesis. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.126813 |
| MSTL | 0.196290 |
| AutoETS | 0.199559 |
| AutoARIMA | 0.203912 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 36% |
| H-stat | 6.88 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.182 |
| Excess Kurtosis | -1.27 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 129.226 |
| Revenue per Share | 4.872 |
| Market Cap | 8,421,127,680 |
| Trailing P/E | 19.23 |
| Forward P/E | 17.10 |
| Beta | 1.60 |
| Profit Margins | 65.95% |
| Website | https://www.tgtherapeutics.com |
As of July 11, 2026, 4:09 a.m. EDT: Speculators are aggressively positioning for a continued rally, evidenced by massive open interest walls at the $60 strike across nearly all expirations and significant volume spikes in out-of-the-money calls. While there is notable put volume at lower strikes ($25-$44), the overwhelming capital allocation is directional bullishness targeting a move toward $60-$65 in the near term, with implied volatility remaining elevated to reflect this uncertainty.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.46762586 |
| Address1 | 3,020 Carrington Mill Blvd. |
| Address2 | Suite 475 |
| All Time High | 233.4375 |
| All Time Low | 0.95625 |
| Ask | 63.78 |
| Ask Size | 1 |
| Audit Risk | 9 |
| Average Analyst Rating | 1.7 - Buy |
| Average Daily Volume10 Day | 2,610,990 |
| Average Daily Volume3 Month | 2,395,927 |
| Average Volume | 2,395,927 |
| Average Volume10Days | 2,610,990 |
| Beta | 1.597 |
| Bid | 47.05 |
| Bid Size | 1 |
| Board Risk | 10 |
| Book Value | 4.114 |
| City | Morrisville |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 10 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 55.01 |
| Current Ratio | 5.809 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 56.925 |
| Day Low | 54.0 |
| Debt To Equity | 129.226 |
| Display Name | TG Therapeutics |
| Earnings Call Timestamp End | 1,778,070,600 |
| Earnings Call Timestamp Start | 1,778,070,600 |
| Earnings Growth | 3.0 |
| Earnings Quarterly Growth | 2.909 |
| Earnings Timestamp | 1,778,070,600 |
| Earnings Timestamp End | 1,785,760,200 |
| Earnings Timestamp Start | 1,785,760,200 |
| Ebitda | 149,580,000 |
| Ebitda Margins | 0.21358 |
| Enterprise To Ebitda | 53.719 |
| Enterprise To Revenue | 11.473 |
| Enterprise Value | 8,035,309,568 |
| Eps Current Year | 1.52517 |
| Eps Forward | 3.2168 |
| Eps Trailing Twelve Months | 2.86 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 212 554 4531 |
| Fifty Day Average | 45.3348 |
| Fifty Day Average Change | 9.675198 |
| Fifty Day Average Change Percent | 0.21341656 |
| Fifty Two Week Change Percent | 46.762585 |
| Fifty Two Week High | 59.3 |
| Fifty Two Week High Change | -4.290001 |
| Fifty Two Week High Change Percent | -0.07234403 |
| Fifty Two Week Low | 25.28 |
| Fifty Two Week Low Change | 29.729998 |
| Fifty Two Week Low Change Percent | 1.1760284 |
| Fifty Two Week Range | 25.28 - 59.3 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,272,893,400,000 |
| Float Shares | 135,104,544 |
| Forward Eps | 3.2168 |
| Forward P E | 17.100845 |
| Free Cashflow | -30,164,876 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 399 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.83054 |
| Gross Profits | 581,665,984 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.07472 |
| Held Percent Institutions | 0.70262 |
| Implied Shares Outstanding | 153,083,580 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,335,744,000 |
| Last Split Factor | 100:5625 |
| Long Business Summary | TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Jiangsu Hengrui Medicine Co. The company was incorporated in 1993 and is based in Morrisville, North Carolina. |
| Long Name | TG Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 8,421,127,680 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_143627354 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | 461,896,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 8,744,134,089 |
| Number Of Analyst Opinions | 7 |
| Open | 56.7 |
| Operating Cashflow | -13,951,000 |
| Operating Margins | 0.1698 |
| Overall Risk | 10 |
| Payout Ratio | 0.0 |
| Peg Ratio | 1.61 |
| Phone | 212 554 4484 |
| Post Market Change | -0.5 |
| Post Market Change Percent | -0.90892565 |
| Post Market Price | 54.51 |
| Post Market Time | 1,783,986,678 |
| Previous Close | 57.12 |
| Price Eps Current Year | 36.06811 |
| Price Hint | 2 |
| Price To Book | 13.371415 |
| Price To Sales Trailing12 Months | 12.024188 |
| Profit Margins | 0.65952003 |
| Quick Ratio | 4.845 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 1.66667 |
| Region | US |
| Regular Market Change | -2.11 |
| Regular Market Change Percent | -3.69398 |
| Regular Market Day High | 56.925 |
| Regular Market Day Low | 54.0 |
| Regular Market Day Range | 54.0 - 56.925 |
| Regular Market Open | 56.7 |
| Regular Market Previous Close | 57.12 |
| Regular Market Price | 55.01 |
| Regular Market Time | 1,783,972,800 |
| Regular Market Volume | 1,852,386 |
| Return On Assets | 0.0855 |
| Return On Equity | 1.1259999 |
| Revenue Growth | 0.696 |
| Revenue Per Share | 4.872 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 3 |
| Shares Outstanding | 153,083,580 |
| Shares Percent Shares Out | 0.19709998 |
| Shares Short | 30,167,445 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 28,182,602 |
| Short Name | TG Therapeutics, Inc. |
| Short Percent Of Float | 0.2848 |
| Short Ratio | 9.8 |
| Source Interval | 15 |
| State | NC |
| Symbol | TGTX |
| Target High Price | 83.0 |
| Target Low Price | 20.0 |
| Target Mean Price | 52.14286 |
| Target Median Price | 50.0 |
| Total Cash | 514,430,016 |
| Total Cash Per Share | 3.63 |
| Total Debt | 753,556,992 |
| Total Revenue | 700,348,992 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 2.86 |
| Trailing P E | 19.234266 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 35.266376 |
| Two Hundred Day Average Change | 19.743622 |
| Two Hundred Day Average Change Percent | 0.55984265 |
| Type Disp | Equity |
| Volume | 1,852,386 |
| Website | https://www.tgtherapeutics.com |
| Zip | 27,560 |